Percheron Therapeutics Limited (PERCF)

Market Cap	5.38M -14.7%
Revenue (ttm)	1.16M -9.5%
Net Income	-6.33M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,667
Open	0.0020
Previous Close	0.0035
Day's Range	0.0020 - 0.0020
52-Week Range	0.0011 - 0.0190
Beta	1.02
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company’s lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: PERCF

Financial Performance

In fiscal year 2025, Percheron Therapeutics's revenue was 1.80 million, a decrease of -39.32% compared to the previous year's 2.97 million. Losses were -14.92 million, 25.2% more than in 2024.

Financial numbers in AUD